A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Clinical trial NCT03606174 · TERMINATED

Trial details

NCT number: NCT03606174
Sponsor: Mirati Therapeutics Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Urothelial Carcinoma Urothelial Carcinoma Bladder Urothelial Carcinoma Ureter Urothelial Carcinoma of the Renal Pelvis and Ureter Urothelial Carcinoma Urethra

Start date: 2018-09-11
Primary completion: 2022-08-03
Enrollment: 260

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.